TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

HORIZANT

GABAPENTIN ENACARBIL
Approved 2011-04-06
3
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
Prescription
First Approved
2011-04-06
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

Companies

Active Ingredient: GABAPENTIN ENACARBIL

HORIZANT Approval History

Loading approval history...

What HORIZANT Treats

2 indications

HORIZANT is approved for 2 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Restless Legs Syndrome
  • Postherpetic Neuralgia
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HORIZANT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. management of postherpetic neuralgia (PHN) in adults. 1.1 Treatment of Restless Legs Syndrome HORIZANT ® is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night. 1.2 Management of Postherpetic Neuralgia HORIZANT is indicated for the management of postherpetic neuralgia (PHN) in adults.

HORIZANT Patents & Exclusivity

Latest Patent: Jun 2029

Patents (16 active)

US8795725 Expires Jun 10, 2029
US8026279 Expires Nov 10, 2026
US8114909 Expires Apr 11, 2026
+ 6 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.